ACHIEVE LIFE SCIENCES, INC. 4

Nancy R. Phelan received a stock option grant for 25,000 shares at $6.18 and an RSU award for 16,700 shares of Achieve Life Sciences, Inc. common stock as equity compensation.

On July 27, 2026, reporting person Nancy R. Phelan of Achieve Life Sciences, Inc. received an equity compensation package consisting of a stock option grant for 25,000 shares of common stock at an exercise price of $6.18 per share and a restricted stock unit (RSU) award for 16,700 shares, both reported as acquisitions. The stock options vest 100% on the earlier of July 27, 2027 or immediately prior to the issuer’s 2027 annual stockholders’ meeting, contingent on continued service, and are exercisable until July 27, 2036. The RSUs likewise vest 100% on the same schedule, each RSU representing the right to receive one share of common stock upon settlement, with no cash price paid at grant. These awards increase Phelan’s derivative and non-derivative beneficial ownership by 25,000 and 16,700 shares, respectively, representing routine equity compensation rather than an open-market purchase or sale; based on the $6.18 option exercise price as a proxy for current value, the option grant represents an underlying value of approximately $154,500 and the RSU grant approximately $103,206, for a combined incremental award value of about $257,706, and her total post-transaction holdings in these awards are 41,700 shares equivalent.

Filing Facts

CIK

949858

Ticker

ACHV

Form

4

Source Type

fda

Accession

0001193125-26-324231

Alert Tier

5